UNSPSC 51372202: Dextropropoxyphene or propoxyphene

This classification denotes an opiate with the molecular formula C22H29NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S2F83W92TK, chemically known as 4-dimethylamino-3-methyl-1,2-diphenyl-2-propoxybutane but generally known as dextropropoxyphene, which bears US NIH Compound Identifier 10100. European Medicines Agency schedules Dextropropoxyphene in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07053MIG. The term DEXTROPROPOXYPHENE is an International Non-Proprietary Name.

UNSPSC 51372202 Dextropropoxyphene or propoxyphene is a Commodity code that in recent state and local procurement activity tracks pharmaceutical supply agreements, emergency-response medications, and multi-source generic drug programs serving public health agencies, health departments, and cooperative purchasing consortia. State and local buyers are acquiring naloxone (opioid-reversal medication), safe drug deactivation systems, and broader generic pharmaceutical inventories through competitive bidding and cooperative purchasing arrangements. The issuing bodies include county health departments, state HHS commissions, and regional multistate cooperative purchasing alliances that procure on behalf of member agencies across multiple jurisdictions. Work solicited under this code involves establishing supply contracts with manufacturers and distributors, managing National Drug Code (NDC) compliance, ensuring FDA Good Manufacturing Practices (cGMP) certification and Drug Supply Chain Security Act (DSCSA) compliance, and meeting quarterly or ongoing delivery schedules to public health facilities.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to its community health building and a response deadline of July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for direct-to-manufacturer prescription fulfillment outside traditional pharmacy benefit managers and group purchasing organizations. The Minnesota Department of Administration's Office of State Procurement, administering the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), issued RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products through authorized wholesalers with responses due March 26, 2026 and July 1, 2026 contract effectiveness. Vendors must maintain substantial insurance coverage (commercial general liability from $2,000,000 to $5,000,000 per occurrence), comply with federal environmental and drug-supply regulations, utilize authorized distribution channels, and accept administrative fees or performance penalties tied to contract compliance.